Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NYSE:QGEN NASDAQ:RARE NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$52.37-1.8%$49.23$21.72▼$54.60$10.20B1.252.14 million shs6.03 million shsQGENQiagen$45.98+0.5%$48.23$37.63▼$51.88$10.17B0.641.35 million shs1.82 million shsRAREUltragenyx Pharmaceutical$28.13-3.4%$28.97$25.81▼$59.50$2.81B0.211.39 million shs3.63 million shsROIVRoivant Sciences$15.04-0.3%$12.22$8.73▼$16.05$10.30B1.158.21 million shs11.80 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-1.80%+2.27%+7.14%+25.50%+101.73%QGENQiagen+0.50%+1.50%-6.58%-1.58%+3.53%RAREUltragenyx Pharmaceutical-3.37%-7.19%-4.19%-24.26%-51.25%ROIVRoivant Sciences-0.33%+6.82%+28.33%+31.35%+25.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$52.37-1.8%$49.23$21.72▼$54.60$10.20B1.252.14 million shs6.03 million shsQGENQiagen$45.98+0.5%$48.23$37.63▼$51.88$10.17B0.641.35 million shs1.82 million shsRAREUltragenyx Pharmaceutical$28.13-3.4%$28.97$25.81▼$59.50$2.81B0.211.39 million shs3.63 million shsROIVRoivant Sciences$15.04-0.3%$12.22$8.73▼$16.05$10.30B1.158.21 million shs11.80 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-1.80%+2.27%+7.14%+25.50%+101.73%QGENQiagen+0.50%+1.50%-6.58%-1.58%+3.53%RAREUltragenyx Pharmaceutical-3.37%-7.19%-4.19%-24.26%-51.25%ROIVRoivant Sciences-0.33%+6.82%+28.33%+31.35%+25.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9422.10% UpsideQGENQiagen 2.27Hold$49.698.06% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50189.73% UpsideROIVRoivant Sciences 3.00Buy$19.9432.56% UpsideCurrent Analyst Ratings BreakdownLatest RARE, QGEN, BBIO, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025ROIVRoivant SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/18/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/18/2025ROIVRoivant SciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.009/18/2025ROIVRoivant SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $20.009/18/2025ROIVRoivant SciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $16.509/18/2025ROIVRoivant SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $22.009/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M45.12N/AN/A($7.71) per share-6.79QGENQiagen$1.98B5.17$3.22 per share14.27$16.05 per share2.86RAREUltragenyx Pharmaceutical$560.23M4.84N/AN/A$2.76 per share10.19ROIVRoivant Sciences$29.05M353.55N/AN/A$7.45 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)QGENQiagen$83.59M$1.6927.1718.692.4118.30%14.77%8.87%11/5/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest RARE, QGEN, BBIO, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AQGENQiagen$0.250.54%N/A14.79%N/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08QGENQiagen0.251.611.35RAREUltragenyx PharmaceuticalN/A2.452.30ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%QGENQiagen70.00%RAREUltragenyx Pharmaceutical97.67%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%QGENQiagen9.00%RAREUltragenyx Pharmaceutical5.50%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableRARE, QGEN, BBIO, and ROIV HeadlinesRecent News About These CompaniesThe Goldman Sachs Group Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20 at 3:33 AM | americanbankingnews.comHC Wainwright Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $20.00September 20 at 2:56 AM | americanbankingnews.comLeerink Partners Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20 at 2:15 AM | americanbankingnews.comGuggenheim Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) StockSeptember 20 at 2:15 AM | americanbankingnews.comBank of America Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $16.50September 20 at 2:15 AM | americanbankingnews.comMatthew Gline Purchases 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 19 at 8:44 PM | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $24.00September 19 at 1:09 PM | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $20.00 Price Target at JPMorgan Chase & Co.September 19 at 9:53 AM | marketbeat.comGuggenheim Increases Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00September 19 at 9:53 AM | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $22.00 at Leerink PartnersSeptember 19 at 9:20 AM | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Given New $16.50 Price Target at Bank of AmericaSeptember 19 at 9:20 AM | marketbeat.comHC Wainwright Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock PriceSeptember 19 at 8:17 AM | marketbeat.comMatthew Gline Acquires 3,315 Shares of Roivant Sciences (NASDAQ:ROIV) StockSeptember 19 at 7:37 AM | insidertrades.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $20.00September 19 at 3:19 AM | americanbankingnews.com29,982 Shares in Roivant Sciences Ltd. $ROIV Purchased by Inspire Investing LLCSeptember 19 at 3:10 AM | marketbeat.comWhich Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Roivant Sciences Ltd. Stock?September 18 at 12:08 PM | aaii.comARoivant Sciences price target raised to $20 from $18 at JefferiesSeptember 18 at 12:08 PM | msn.comMontes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?September 18 at 11:36 AM | zacks.comRoivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive ResultsSeptember 18 at 11:11 AM | insidermonkey.comRoivant Sciences (NASDAQ:ROIV) Hits New 1-Year High - What's Next?September 18 at 9:56 AM | marketbeat.comRoivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune DiseaseSeptember 17 at 4:53 PM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025RARE, QGEN, BBIO, and ROIV Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$52.37 -0.96 (-1.80%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$53.26 +0.90 (+1.71%) As of 09/19/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Qiagen NYSE:QGEN$45.98 +0.24 (+0.52%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$45.94 -0.04 (-0.10%) As of 09/19/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Ultragenyx Pharmaceutical NASDAQ:RARE$28.13 -0.98 (-3.37%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$28.37 +0.24 (+0.85%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Roivant Sciences NASDAQ:ROIV$15.04 -0.05 (-0.33%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$14.92 -0.12 (-0.82%) As of 09/19/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
